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inserted. Chest X-ray showed overt congestion 
(FIGurE 1A). The initial transthoracic echocardiog-
raphy revealed extreme dysfunction of moderate-
ly dilated left ventricle (left ventricular ejection 
fraction [LVEF], 10%; left ventricular end-diastolic 
diameter [LVEDd], 61 mm). Right ventricular sys-
tolic function was normal and no signs of acute 
pulmonary embolism, cardiac tamponade, or val-
vular pathology were noted (FIGurE 1BC). Baseline 
Fulminant myocarditis (FM) is a rare subtype of 
acute myocarditis characterized by a rapid onset, 
dramatic course, and poor outcome.1 Epidemio-
logical data are scarce but only 27 of 1098 patients 
(2.5%) with more than 14 infiltrating lymphocytes 
in cardiac biopsy samples met the criteria of FM 
in the Marburg Myocarditis Registry.2 The World 
Heart Federation consensus introduced a cut-off 
value of 50 infiltrating cells/mm2 or higher as a di-
agnostic criterion.3 The etiology is noninfectious 
and infectious with predominance of cardiotropic 
viruses. Mechanical circulatory support including 
intraaortic balloon pump (IABP), extracorporeal 
membrane oxygenation (ECMO), and ventricu-
lar assist devices has become the cornerstone of 
treatment for circulatory collapse.4 A treatment 
of FM has not been precisely defined. Intravenous 
immunoglobulins are used in biopsy-confirmed 
viral myocarditis and immunosuppression in au-
toreactive myocarditis.5
A previously fit and well 30-year-old physical 
worker was admitted to our intensive care unit in 
a critical state because of acute chest discomfort 
and cardiopulmonary collapse of an unknown or-
igin. Initial electrocardiography showed ST-seg-
ment elevation in leads V1–V3 and deep ST-seg-
ment depression in leads V5–V6. The patient was 
referred for urgent coronary angiography but it 
did not reveal any abnormalities. Because of per-
sistent hypotension of 80/40 mmHg, IABP was 
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FIGurE 1 A – initial A-P chest X-ray with overt pulmonary congestion and enlarged cardiac silhouette; BC – admission transthoracic echocardio-
gram (TTE) documenting severe left ventricular (LV) dysfunction (LV ejection fraction [LVEF], 10%); D – LV endomyocardial biopsy sample (hematoxylin 
and eosin staining) showing lymphocytic infiltrates (blue arrows); E – destruction of cardiomyocytes and reactive fibrosis (black arrows), F – immuno-
histochemistry: CD3+ T cell infiltrates (green arrow); G – a marked decrease of pulmonary congestion and reduction of the cardiac silhouette size; 
HI – TTE on day 9 of hospitalization: near-to-normal LV contractility (EF, 50%)
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laboratory tests were as follows: white blood cell 
count, 23 G/l; C-reactive protein (CRP), 120 mg/l 
(upper normal limit [UNL], <5); alanine trans-
aminase, 106 U/l (UNL, <41); aspartate trans-
aminase, 251 U/l (UNL, <40); international nor-
malized ratio, 1.92 (UNL, 0.85–1.15); creatinine 
kinase (CK), 4583 U/l (UNL, <190); CK-MB, 126 
U/l (UNL, <24); and high-sensitivity troponin T 
(hs-TnT), 4.03 ng/ml (UNL, <0.014). IABP was 
replaced by the venoarterial ECMO system. A 
working diagnosis of fulminant myocarditis was 
made, and the patient was scheduled for urgent 
endomyocardial biopsy, which was performed un-
der fluoroscopic and echocardiographic guidance. 
Hematoxyline and eosin staining showed infiltra-
tion of mononuclear cells (FIGurE 1D, arrows), de-
struction of cardiomyocytes, and reactive fibrosis 
(FIGurE 1E, arrows). Immunohistochemistry indi-
cated the infiltrating cells to be CD3+ T cells and 
CD68+ macrophages (FIGurE 1F, arrow). Histopath-
ological and immunohistochemistry studies con-
firmed the diagnosis of myocarditis. Based on re-
al-time polymerase chain reaction and in situ hy-
bridization, the offending factor was diagnosed 
to be parvovirus B19. An intravenous immuno-
globulin treatment with Pentaglobin© was ad-
ministered for 3 days. The patient’s clinical status 
and chest X-ray results were gradually improving 
(FIGurE 1G). On day 16, ECMO was safely removed. 
On day 28, the patient was transferred to a cardi-
ac unit, and after 4 days, he was discharged home 
in a good clinical condition. Final echocardiogra-
phy revealed normalization of the left ventricu-
lar cavity (LVEDd, 52 mm; LVESd, 32 mm) and 
improvement of LVEF to 50% (FIGurE 1HI). The re-
maning parameters also normalized (CRP levels, 
3.8 mg/l; CK, 78 U/l; CK-MB, 26 U/l; and hs-TnT, 
0.028 ng/ml).
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